1. MAPK/ERK Pathway
    Protein Tyrosine Kinase/RTK
    Autophagy
  2. Raf
    VEGFR
    PDGFR
    FLT3
    c-Kit
    Autophagy

Sorafenib (Synonyms: Bay 43-9006)

Cat. No.: HY-10201 Purity: 99.83%
Data Sheet SDS Handling Instructions

Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

For research use only. We do not sell to patients.
Sorafenib Chemical Structure

Sorafenib Chemical Structure

CAS No. : 284461-73-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
100 mg $50 In-stock
500 mg $65 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Sorafenib:

    Sorafenib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

    Sorafenib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

    Sorafenib purchased from MCE. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784.

    Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

    Sorafenib purchased from MCE. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229.

    The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

    Sorafenib purchased from MCE. Usage Cited in: Endocr J. 2017 Aug 31.

    Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

    Sorafenib purchased from MCE. Usage Cited in: Endocr J. 2017 Aug 31.

    Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

    Sorafenib purchased from MCE. Usage Cited in: Br J Cancer. 2017 Aug 29.

    The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor–AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

    IC50 & Target

    IC50: 6 nM (Raf-1), 20 nM (VEGFR-3), 22 nM (BRAF), 57 nM (PDGFR-β), 58 nM (Flt3), 68 nM (c-KIT), 90 nM (VEGFR-2)[1]

    In Vitro

    Sorafenib (BAY 43-9006) also inhibits BRAFwt (IC50=22 nM), BRAFV599E (IC50=38 nM), VEGFR-2 (IC50=90 nM), VEGFR-3 (IC50=20 nM), PDGFR-β (IC50=57 nM), c-KIT (IC50=68 nM), and Flt3 (IC50=58 nM) in biochemical assays. In MDA-MB-231 breast cancer cells, Sorafenib completely blocks activation of the MAPK pathway. Cells are preincubated with Sorafenib (0.01 to 3 μM), and dose-dependent inhibition of basal MEK 1/2 and ERK 1/2 phosphorylation (IC50, 40 and 100 nM, respectively)[1].

    In Vivo

    Sorafenib demonstrates broad oral antitumor efficacy in panel of human tumor xenograft models. Sorafenib is given orally at 7.5 to 60 mg/kg. There is no lethality and no increase in weight loss in any treated group relative to the corresponding control group. Daily oral administration of Sorafenib (30 to 60 mg/kg) produces complete tumor stasis during treatment in five of the six models[1]. The survival rate is 73.3 % in Diethyl nitrosamine (DENA) group and 83.3 % in Sorafenib group compared to 100 % in the normal control group. DENA group shows a significant increase in liver index (1.51-fold increase, p<0.05) compared to normal control group, while treatment with Sorafenib shows significant decrease (p<0.05) in liver index when compared to DENA group. The liver index in Sorafenib group significantly decreases to lower than its value in the normal control[2].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00287495 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Kaposi's Sarcoma|HHV-8|KSHV February 1, 2006 Phase 1
    NCT00090545 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Prostate Cancer August 2004 Phase 2
    NCT00326495 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Metastatic Colorectal Cancer May 10, 2006 Phase 2
    NCT00533585 M.D. Anderson Cancer Center|Bayer Lung Cancer May 2006 Phase 1
    NCT00098254 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Non-Small-Cell Lung Carcinoma December 2004 Phase 2
    NCT00436215 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Ovarian Neoplasm|Fallopian Tube Cancer|Primary Peritoneal Cancer December 2006 Phase 2
    NCT00430235 British Columbia Cancer Agency Adenocarcinoma of the Prostate March 2007 Phase 2
    NCT00253370 National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Metastatic Gastric Cancer|Advanced Unresectable Gastric Cancer October 2005 Phase 2
    NCT01982097 Bayer Carcinoma, Renal Cell January 10, 2014
    NCT00095459 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms November 2, 2004 Phase 1
    NCT00619541 Italian Trial in Medical Oncology Hepatocellular Carcinoma January 2007 Phase 2
    NCT00483301 Mt. Sinai Medical Center, Miami|Celgene Corporation|Bayer Malignant Melanoma May 2007 Phase 2
    NCT00199160 Jules Bordet Institute Head and Neck Neoplasms April 2005 Phase 2
    NCT01508364 Bayer Carcinoma, Renal Cell July 2012
    NCT00727233 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neurofibromatosis Type I|Plexiform Neurofibroma July 8, 2008 Phase 1
    NCT00287495 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Kaposi's Sarcoma|HHV-8|KSHV February 1, 2006 Phase 1
    NCT00090545 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Prostate Cancer August 2004 Phase 2
    NCT00326495 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Metastatic Colorectal Cancer May 10, 2006 Phase 2
    NCT00533585 M.D. Anderson Cancer Center|Bayer Lung Cancer May 2006 Phase 1
    NCT00098254 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Non-Small-Cell Lung Carcinoma December 2004 Phase 2
    NCT00436215 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Ovarian Neoplasm|Fallopian Tube Cancer|Primary Peritoneal Cancer December 2006 Phase 2
    NCT00430235 British Columbia Cancer Agency Adenocarcinoma of the Prostate March 2007 Phase 2
    NCT00253370 National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Metastatic Gastric Cancer|Advanced Unresectable Gastric Cancer October 2005 Phase 2
    NCT01982097 Bayer Carcinoma, Renal Cell January 10, 2014
    NCT00095459 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neoplasms November 2, 2004 Phase 1
    NCT00619541 Italian Trial in Medical Oncology Hepatocellular Carcinoma January 2007 Phase 2
    NCT00483301 Mt. Sinai Medical Center, Miami|Celgene Corporation|Bayer Malignant Melanoma May 2007 Phase 2
    NCT00199160 Jules Bordet Institute Head and Neck Neoplasms April 2005 Phase 2
    NCT01508364 Bayer Carcinoma, Renal Cell July 2012
    NCT00727233 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Neurofibromatosis Type I|Plexiform Neurofibroma July 8, 2008 Phase 1
    NCT02122003 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Metastatic Renal Cell Carcinoma May 2014 Phase 2
    NCT01425216 Tirgan, Michael H., M.D. Keloids March 2013 Phase 2
    NCT00478114 Mahidol University|Bayer Renal Cell Carcinoma May 2007 Phase 3
    NCT02636426 VU University Medical Center Neoplasms September 2015 Phase 1
    NCT02288507 University of Hawaii Hepatocellular Cancer November 2014 Phase 1
    NCT00780169 Ottawa Hospital Research Institute|Bayer Metastatic Colorectal Cancer October 2008 Phase 1
    NCT00544609 Spanish Oncology Genito-Urinary Group Bladder Cancer December 2007 Phase 1
    NCT02084732 Instituto Nacional de Cancerologia, Columbia Thyroid Cancer October 2013 Phase 2
    NCT00997022 Columbia University|Bayer|Amgen Hepatocellular Cancer May 2009 Phase 1
    NCT00875745 Indiana University School of Medicine|Bayer|Indiana University Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes April 2009 Phase 1
    NCT00480389 University Health Network, Toronto|Bayer Renal Cell Carcinoma|Metastatic Disease May 2007 Phase 2
    NCT02733809 King Saud University|King Faisal Specialist Hospital & Research Center Hepatocellular Carcinoma January 2014 Phase 4
    NCT02021929 University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI) Hepatopulmonary Syndrome March 2014 Phase 2
    NCT00933777 University of Cologne Unspecified Adult Solid Tumor, Protocol Specific|Non-Small Cell Lung Cancer July 2009 Phase 1
    NCT00808145 Lahey Clinic Hepatocellular Carcinoma February 2009 Phase 2
    NCT01510756 Thomas Kipps|Bayer|University of California, San Diego Chronic Lymphocytic Leukemia December 2011 Phase 2
    NCT01029418 National Cancer Centre, Singapore Hepatocellular Carcinoma November 2009 Phase 1|Phase 2
    NCT00954278 University of Wisconsin, Madison|Bayer Carcinoma, Non Small Cell Lung July 2009 Phase 1
    NCT01906216 Fourth Military Medical University Hepatocellular Carcinoma September 2013 Phase 2|Phase 3
    NCT01203787 University of Florida Hepatocellular Carcinoma December 2010 Phase 4
    NCT01342627 Centro di Riferimento Oncologico - Aviano Metastatic Renal Cell Carcinoma October 2010 Phase 2
    NCT01556815 Shandong Cancer Hospital and Institute PHENYTOIN/SORAFENIB [VA Drug Interaction]|Liver Neoplasms|Carcinoma, Hepatocellular|Digestive System Neoplasms|Neoplasms by Site|Liver Diseases|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]|HBV May 2012 Phase 2
    NCT00703365 Mahidol University|Bayer|Chulalongkorn University|Bumrungrad International Hospital Carcinoma, Hepatocellular February 2008 Phase 2
    NCT02867280 Sun Yat-sen University Hepatocellular Carcinoma|Recurrence June 2016 Phase 3
    NCT02560779 Tracon Pharmaceuticals Inc. Hepatocellular Carcinoma January 2016 Phase 1|Phase 2
    NCT00810394 University of California, Davis|Bayer Unspecified Adult Solid Tumor, Protocol Specific December 2008 Phase 2
    NCT00924807 Beth Israel Medical Center|Bayer Prostate Cancer September 2008 Phase 1|Phase 2
    NCT01471353 University of Florida Colorectal Cancer Metastatic November 2011 Phase 2
    NCT01328223 China Medical University Hospital Hepatocellular Carcinoma September 2010 Phase 2
    NCT00854620 Stanford University Carcinoma, Renal Cell|Kidney Disease|Kidney Cancer December 2007 Phase 2
    NCT00572078 Safi Shahda|Genentech, Inc.|Bayer|Indiana University SOLID TUMORS July 2008 Phase 1
    NCT02196857 M.D. Anderson Cancer Center|Bayer Leukemia February 2015 Phase 2
    NCT00801801 Francisco Robert,MD|Sanofi|Bayer|University of Alabama at Birmingham Non Squamous Cell Lung Cancer|Non Small Cell Lung Cancer January 2008 Phase 2
    NCT00956436 Biogen Hepatocellular Carcinoma August 2009 Phase 1
    NCT01141309 Memorial Sloan Kettering Cancer Center Thyroid Cancer June 2010 Phase 2
    NCT01507064 Cardarelli Hospital Hepatocellular Carcinoma January 2012 Phase 2
    NCT00892658 University Health Network, Toronto Hepatocellular Carcinoma January 2009 Phase 1
    NCT01254890 M.D. Anderson Cancer Center|Bayer|Onyx Therapeutics, Inc.|Celgene Leukemia January 2011 Phase 1|Phase 2
    NCT00887107 Leiden University Medical Center Thyroid Cancer October 2007 Phase 2
    NCT00917462 Memorial Sloan Kettering Cancer Center|Bayer Esophageal Cancer|Gastroesophageal Junction Cancer June 2009 Phase 2
    NCT00813293 Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Bayer|Onyx Therapeutics, Inc.|National Cancer Institute (NCI) Hepatocellular Cancer January 2009 Phase 2
    NCT00565370 Asan Medical Center Advanced Gastric Cancer November 2007 Phase 1|Phase 2
    NCT01900002 M.D. Anderson Cancer Center|Bayer Liver Cancer September 13, 2013 Phase 2
    NCT00942682 Dana-Farber Cancer Institute|Novartis|Bayer Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor July 2009 Phase 1
    NCT01338857 New York University School of Medicine|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma neurofibromatosis1 (NF1)|Recurrent or Progressive Optic Pathway Gliomas (OPG)|Recurrent or Progressive Low-grade Glioma April 2011 Phase 2
    NCT01444807 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Metastatic Renal Cell Carcinoma December 2011 Phase 2
    NCT00846131 Northwestern University|National Cancer Institute (NCI) Hepatocellular Carcinoma February 2009 Phase 1
    NCT00862082 Proacta, Incorporated Hepatocellular Carcinoma March 2009 Phase 1|Phase 2
    NCT00375310 Indiana University School of Medicine|Amgen|Indiana University Pancreatic Cancer|Adenocarcinoma of the Pancreas September 2006 Phase 1
    NCT01833299 Sun Yat-sen University Hepatocellular Carcinoma|Face Cancer January 2010 Phase 4
    NCT01025453 Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer Thyroid Cancer December 2009 Phase 2
    NCT01561833 Yale University T Cell Lymphoma October 2009 Phase 1
    NCT00893373 Technische Universität Dresden|Bayer Acute Myeloid Leukemia (AML) March 2009 Phase 2
    NCT00461851 Yale University|Bayer Bladder Cancer March 2007 Phase 2
    NCT00532025 Johannes Gutenberg University Mainz Carcinoma, Non-Small-Cell Lung September 2007 Phase 2
    NCT00605566 University Health Network, Toronto Neuroendocrine Tumors January 2008 Phase 2
    NCT02311205 Asan Medical Center|Bayer Hepatocellular Carcinoma|Metastasis December 2014 Phase 2
    NCT01041482 Chinese Academy of Medical Sciences|Beijing University of Chinese Medicine|China Medical University, China|Peking Union Medical College Hospital|Tianjin Medical University|Shanghai Jiao Tong University School of Medicine|Changhai Hospital|Zhejiang University|Fudan University|Jiangsu Province Centers for Disease Control and Prevention|Central South University|Sichuan University|Huazhong University of Science and Technology Renal Cell Carcinoma November 2008 Phase 2
    NCT02474290 Nanfang Hospital of Southern Medical University|Peking University People's Hospital|Fujian Medical University Union Hospital|Guangdong General Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Zhujiang Hospital|Guangzhou First People's Hospital Acute Myeloid Leukemia|Hematopoietic Stem Cell Transplantation June 2015 Phase 4
    NCT01319942 China Medical University Hospital Hepatocellular Carcinoma June 2010
    NCT00525161 Suleiman Massarweh|Bayer|University of Kentucky Breast Cancer October 2007 Phase 2
    NCT00984425 Istituto Clinico Humanitas Solid Tumors September 2009 Phase 1
    NCT02332031 Bayer Drug Interactions February 2015 Phase 1
    NCT00892424 University Health Network, Toronto Liver Metastasis|Cancer November 2008 Phase 1|Phase 2
    NCT00870532 National Cancer Centre, Singapore Non-Small Cell Lung Cancer June 2008 Phase 1
    NCT00767468 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Liver Cancer October 2008 Phase 1
    NCT00445042 The Methodist Hospital System|Bayer|Amgen Carcinoma, Renal Cell November 2005 Phase 2
    NCT00543335 M.D. Anderson Cancer Center|Bayer Lung Cancer January 2008 Phase 1
    NCT01334710 Emory University|OSI Pharmaceuticals Liver Cancer March 2011 Phase 2
    NCT01534260 Hamid Sayar|Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme Corp.|Indiana University Acute Myeloid Leukemia February 10, 2012 Phase 1|Phase 2
    NCT00815295 Duke University|Bayer Squamous Cell Cancer January 2008 Phase 1|Phase 2
    NCT02069145 OncoMed Pharmaceuticals, Inc. Hepatocellular Cancer|Liver Cancer January 2014 Phase 1
    NCT01032850 New Mexico Cancer Care Alliance|Bayer Hepatocellular Carcinoma September 2009 Phase 2
    NCT00764972 McGill University Metastatic Breast Cancer October 2007 Phase 1|Phase 2
    NCT00703638 Masonic Cancer Center, University of Minnesota Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma May 2008 Phase 1
    NCT02150317 Eastern Hepatobiliary Surgery Hospital Advanced Hepatocellular Carcinoma January 2014
    NCT00541840 Grupo Espanol de Investigacion en Sarcomas Soft Tissue Sarcoma October 2007 Phase 1|Phase 2
    NCT02298348 New Approaches to Neuroblastoma Therapy Consortium|University of California, San Francisco|Children's Hospital Los Angeles|Lucile Packard Children's Hospital|Children's Hospital Medical Center, Cincinnati|University of Michigan|Seattle Children's Hospital|Dana-Farber Cancer Institute|The Hospital for Sick Children|Children's Healthcare of Atlanta|University of Chicago|Cook Children's Health Care System|Memorial Sloan Kettering Cancer Center|Children's Hospital Colorado Neuroblastoma April 2015 Phase 1
    NCT00597493 Duke University|Bayer|Schering-Plough Recurrent Glioblastoma Multiforme September 2007 Phase 2
    NCT01539018 Egyptian Society of Liver Cancer Advanced Hepatocellular Carcinoma January 2012 Phase 2
    NCT00548899 German Breast Group|Bayer Breast Cancer November 2007 Phase 2
    NCT01398501 Massachusetts General Hospital|Dana-Farber Cancer Institute Acute Myeloid Leukemia August 2011 Phase 1
    NCT00794235 University of Zurich Melanoma Stage III or IV|No Prior Chemotherapy December 2008 Phase 2
    NCT00754923 Ohio State University Comprehensive Cancer Center|Bayer Lung Cancer October 2008 Phase 2
    NCT02530476 M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc|National Cancer Institute (NCI) Leukemia|Acute Myeloid Leukemia December 8, 2015 Phase 1|Phase 2
    NCT01159327 National Cancer Center, Korea|Bayer Small Cell Lung Cancer December 2010 Phase 2
    NCT01171651 Jennerex Biotherapeutics|SillaJen, Inc. Carcinoma, Hepatocellular August 2009 Phase 2
    NCT02599337 Yabao Pharmaceutical Group Fasting July 2015 Phase 1
    NCT01263951 Abramson Cancer Center of the University of Pennsylvania|Bayer|Novartis Pharmaceuticals Differentiated Thyroid Cancer November 2010 Phase 2
    NCT00562523 Bayer|Amgen Neoplasms November 2007 Phase 1
    NCT00510289 Duke University|Bayer Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic July 2006 Phase 2
    NCT00884416 University Hospital, Geneva|Bayer Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma March 2009 Phase 1
    NCT00768937 Medical University of Vienna Hepatocellular Carcinoma September 2008 Phase 1|Phase 2
    NCT02691780 Samsung Medical Center Refractory Solid Tumors December 23, 2016
    NCT00622479 Bayer Carcinoma, Renal Cell May 2008 Phase 1
    NCT01613846 Technische Universität München Renal Cell Carcinoma May 2012 Phase 3
    NCT00880542 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Sarcoma August 2008 Phase 2
    NCT02529761 Fourth Military Medical University Hepatocellular Carcinoma August 2015
    NCT00827177 ArQule Advanced Solid Tumors September 2009 Phase 1
    NCT01804374 Italian Sarcoma Group Metastatic Osteosarcoma|Relapsed Osteosarcoma June 2011 Phase 2
    NCT01005875 University of Alabama at Birmingham|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Hepatocellular Carcinoma|Liver Cancer November 2009
    NCT01091207 Samsung Medical Center|Korean GIST Study Group Gastrointestinal Stromal Tumors November 2009 Phase 2
    NCT00609804 SCRI Development Innovations, LLC|Bayer|OSI Pharmaceuticals Non-Small Cell Lung Cancer March 2008 Phase 2
    NCT01640665 Yale University|Bayer Metastatic Breast Cancer|Gastrointestinal Tumors July 2012 Phase 1
    NCT00694291 Fox Chase Cancer Center|Bayer Prostate Cancer June 2008 Phase 2
    NCT00639262 Sidney Kimmel Cancer Center at Thomas Jefferson University|Bayer|Thomas Jefferson University Brain Metastases|Primary Brain Tumors March 2008 Phase 1
    NCT00922584 Chinese Society of Lung Cancer Non-Small Cell Lung Cancer December 2008 Phase 2
    NCT00933816 Japan Liver Oncology Group Hepatocellular Carcinoma July 2009 Phase 1|Phase 2
    NCT00772694 Fondation Wygrajmy Zdrowie Testicular Cancer September 2008 Phase 2
    NCT01531361 M.D. Anderson Cancer Center Advanced Cancers February 2012 Phase 1
    NCT01539681 Bayer Hepatocellular Carcinoma February 2012
    NCT00785226 Bayer Advanced Cancer November 2008 Phase 1|Phase 2
    NCT01851408 National Cancer Institute (NCI)|M.D. Anderson Cancer Center Melanoma|Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma April 2006 Phase 2
    NCT00576056 University of Pittsburgh|Bayer Carcinoma, Hepatocellular January 2008 Phase 2
    NCT02562755 SillaJen, Inc. Hepatocellular Carcinoma (HCC) October 2015 Phase 3
    NCT00414388 Oncology Specialists, S.C. Prostate Cancer December 2006 Phase 1|Phase 2
    NCT00837148 Memorial Sloan Kettering Cancer Center|Bayer Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor February 2009 Phase 2
    NCT00390325 National Cancer Institute (NCI) Multiple Endocrine Neoplasia|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Medullary Carcinoma October 2006 Phase 2
    NCT00064350 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lung Cancer May 2004 Phase 2
    NCT01762150 Beijing Cancer Hospital|Bayer Renal Cell Carcinoma June 2011 Phase 2
    NCT01481870 Yamagata University Metastatic Renal Cell Carcinoma January 2010 Phase 3
    NCT00964743 H. Lee Moffitt Cancer Center and Research Institute|Bayer Neoplastic Meningitis August 2009
    NCT02961998 Sun Yat-sen University Hepatocellular Carcinoma July 2015 Phase 4
    NCT00625378 Bayer|ICON Clinical Research Neoplasms December 21, 2007 Phase 3
    NCT00093613 National Cancer Institute (NCI) Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor December 2004 Phase 1
    NCT00618384 Heinrich-Heine University, Duesseldorf Hepatocellular Carcinoma January 2008 Phase 2
    NCT00654238 University of Pennsylvania Metastatic Differentiated Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer|Metastatic Medullary Thyroid Cancer February 2006 Phase 2
    NCT01214343 Ministry of Health, Labour and Welfare, Japan Advanced Hepatocellular Carcinoma|Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Neoplasms October 2010 Phase 3
    NCT01230697 University of Turin, Italy Kidney Cancer|Liver Cancer June 2010
    NCT01100242 New Mexico Cancer Care Alliance Metastatic Renal Cell Carcinoma April 2010 Phase 2
    NCT01005797 Medical University of South Carolina|Novartis Pharmaceuticals Renal Cancer|Non Small Cell Lung Cancer (NSCLC)|Soft Tissue Sarcoma November 2009 Phase 1
    NCT02323906 Celgene Carcinoma, Hepatocellular January 16, 2015 Phase 1
    NCT00647426 Abramson Cancer Center of the University of Pennsylvania Non-Small Cell Lung Cancer November 2007 Phase 2
    NCT00392821 SCRI Development Innovations, LLC|Novartis|Bayer Kidney Cancer December 2006 Phase 1|Phase 2
    NCT01226056 Southern Europe New Drug Organization|Novartis|Bayer Advanced Solid Tumors March 2009 Phase 1|Phase 2
    NCT01901692 Asan Medical Center Hepatocellular Carcinoma July 2013 Phase 2
    NCT01008917 University of California, San Francisco|Northwestern University Hepatocellular Carcinoma November 17, 2009 Phase 1
    NCT01189370 University of Kansas Medical Center|Bayer Renal Cell Cancer June 2008 Phase 2
    NCT01480817 Seoul National University Hospital Hepatocellular Carcinoma June 2012 Phase 2
    NCT00618982 Bayer Carcinoma, Renal Cell February 2008 Phase 2
    NCT01932385 Qingdao Central Hospital Liver Cancer August 2013 Phase 2|Phase 3
    NCT00609934 University Health Network, Toronto Renal Cell Carcinoma December 2007 Phase 1|Phase 2
    NCT00586105 Bayer Carcinoma, Renal Cell December 2005 Phase 3
    NCT01714609 Yale University|Onyx Therapeutics, Inc. Clinically Significant Portal Hypertension August 2011 Phase 2
    NCT01893099 Prof. Serge Leyvraz|Centre Hospitalier Universitaire Vaudois Ocular Melanoma June 2013 Phase 1
    NCT00606125 Bayer Neoplasms May 2007 Phase 1
    NCT02185560 Bayer Thyroid Carcinoma June 27, 2014
    NCT00562913 Bayer Cancer December 2007 Phase 1
    NCT00882869 Aegera Therapeutics|Chinese University of Hong Kong Advanced Hepatocellular Carcinoma March 2009 Phase 1|Phase 2
    NCT01098760 Bayer Hepatocellular Carcinoma August 2010 Phase 4
    NCT02672488 Tianjin Medical University Cancer Institute and Hospital|First Affiliated Hospital of Harbin Medical University|Harbin Medical University|Liaoning Tumor Hospital & Institute|Shanghai Zhongshan Hospital|Fudan University Hepatocellular Carcinoma December 2015 Phase 2
    NCT01005199 Swiss Group for Clinical Cancer Research Liver Cancer November 2009 Phase 2
    NCT03037437 The University of Texas Health Science Center at San Antonio Hepatocellular Cancer January 2017 Phase 2
    NCT00844688 Combined Military Hospital, Pakistan|Bayer Hepatocellular Carcinoma September 2008 Phase 2
    NCT00999843 Fudan University Hepatocellular Carcinoma October 2009 Phase 1|Phase 2
    NCT00595985 Fudan University Gastric Cancer July 2007 Phase 2
    NCT00411671 M.D. Anderson Cancer Center|United States Department of Defense|Bayer Lung Cancer November 2006 Phase 2
    NCT03170895 The University of Hong Kong AML|FLT3-ITD Mutation July 1, 2017 Phase 2
    NCT00759928 SCRI Development Innovations, LLC|Bayer Refractory Solid Tumors October 2008 Phase 1
    NCT00613145 SCRI Development Innovations, LLC|Bayer Refractory Malignancy February 2008 Phase 1
    NCT01075113 Virginia Commonwealth University|Massey Cancer Center Liver Cancer August 10, 2010 Phase 1
    NCT01618253 Medical College of Wisconsin Hepatocellular Carcinoma|Hepatocellular Cancer|Hepatoma|Liver Cancer June 2012 Phase 1
    NCT02330783 Beijing Cancer Hospital Metastatic Renal Cell Carcinoma December 2014 Phase 2
    NCT01470495 Southwest Hospital, China|Hunan Province Tumor Hospital|Tang-Du Hospital|Xijing Hospital|First Affiliated Hospital of Guangxi Medical University|First Affiliated Hospital Xi'an Jiaotong University|Anhui Provincial Hospital|Xiangya Hospital of Central South University|Xinqiao Hospital of Chongqing|Xinjiang Tumor Hospital|People's Hospital of Guangxi|Henan Cancer Hospital|People's Hospital of Sichuan|Huaxi Hospital HCC|Radiofrequency Ablation|Sorafenib January 2015
    NCT00866320 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Kidney Cancer February 2006 Phase 2
    NCT01030783 AVEO Pharmaceuticals, Inc. Advanced Renal Cell Carcinoma December 2009 Phase 3
    NCT01605734 Shandong Cancer Hospital and Institute PHENYTOIN/SORAFENIB [VA Drug Interaction]|Carcinoma, Hepatocellular July 2012 Phase 2
    NCT02624700 Virginia Commonwealth University|Eli Lilly and Company Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer January 28, 2016 Phase 2
    NCT01128998 National Health Research Institutes, Taiwan|National Cheng-Kung University Hospital Advanced Solid Tumors November 2009 Phase 1
    NCT02716766 The University of Hong Kong Carcinoma, Hepatocellular|Secondary March 2016 Phase 2
    NCT00557830 Accelerated Community Oncology Research Network|Bayer Renal Cell Carcinoma January 2008 Phase 2
    NCT00373373 University Hospital Muenster|Bayer Acute Myeloid Leukemia September 2006 Phase 2
    NCT01736878 Eanm Research Ltd Medullary Thyroid Carcinoma October 2012 Phase 2
    NCT00405366 UNC Lineberger Comprehensive Cancer Center|Doris Duke Charitable Foundation|Bayer|Amgen Kidney Cancer November 2006 Early Phase 1
    NCT00839111 Fudan University Colorectal Neoplasms November 2008 Phase 2
    NCT00714948 Memorial Sloan Kettering Cancer Center|Bayer Bladder Cancer|URINARY BLADDER July 2008 Phase 2
    NCT00844883 Sidney Kimmel Comprehensive Cancer Center|Bayer|Biocompatibles UK Ltd Hepatocellular Carcinoma|Hepatoma February 2009 Phase 2
    NCT02834546 University Hospital, Bordeaux Hepatocellular Carcinoma (HCC) October 2016
    NCT00943943 M.D. Anderson Cancer Center|Bayer|Genzyme, a Sanofi Company|Amgen|National Cancer Institute (NCI)|Georgia Institute of Technology Acute Myelogenous Leukemia|Leukemia October 29, 2010 Phase 1
    NCT00825734 SCRI Development Innovations, LLC|Bayer|Bristol-Myers Squibb Metastatic Breast Cancer March 2009 Phase 1|Phase 2
    NCT00863746 Bayer Carcinoma|Non-Small-Cell Lung April 2009 Phase 3
    NCT01303341 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|Recurrent Melanoma|Refractory Malignant Solid Neoplasm|Stage III Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma February 18, 2011 Phase 1
    NCT00131937 National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma October 2005 Phase 2
    NCT00864032 University of California, Davis|Bayer Soft Tissue Sarcoma March 2009 Phase 1|Phase 2
    NCT00126568 National Cancer Institute (NCI) Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer June 2005 Phase 2
    NCT01076010 AVEO Pharmaceuticals, Inc. Advanced Renal Cell Carcinoma March 2010 Phase 3
    NCT00300885 Bayer Carcinoma, Non-Small Cell Lung February 2006 Phase 3
    NCT00602862 Radboud University|Dutch Cancer Society Clear Cell Renal Cell Carcinoma July 2007
    NCT02538393 Bayer Biological Availability November 20, 2015 Phase 1
    NCT02504983 Chang Gung Memorial Hospital Hepatocellular Carcinoma August 2015 Phase 4
    NCT02406508 Delcath Systems Inc. Hepatocellular Carcinoma (HCC) October 2014 Phase 2
    NCT01634893 The University of Texas Health Science Center at San Antonio Refractory or Relapsed Solid Tumors June 2012 Phase 1
    NCT02425605 Yonsei University Hepatocellular Carcinoma January 2015 Phase 2
    NCT00712790 Singapore Clinical Research Institute|National Medical Research Council (NMRC), Singapore|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sirtex Medical Hepatocellular Carcinoma June 2008 Phase 1|Phase 2
    NCT00943449 4SC AG Hepatocellular Carcinoma July 2009 Phase 2
    NCT00848640 Egyptian Foundation For Cancer Research Metastatic Renal Cell Carcinoma October 2008 Phase 2
    NCT00610246 University Health Network, Toronto Cancer May 2007 Phase 1
    NCT00112671 National Cancer Institute (NCI) Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder April 2005 Phase 2
    NCT01608139 M.D. Anderson Cancer Center|Sabinsa Corporation Advanced Cancers November 2012 Phase 1
    NCT00510250 University Health Network, Toronto|Bayer Cancer of the Cervix June 2007 Phase 1|Phase 2
    NCT02114658 Bayer Thyroid Carcinoma April 2014 Phase 2
    NCT01849588 Massachusetts General Hospital Hepatocellular Cancer May 2013 Phase 4
    NCT02072486 Roswell Park Cancer Institute|National Cancer Institute (NCI) Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Hepatocellular Carcinoma|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Childhood Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma November 18, 2013
    NCT00093626 National Cancer Institute (NCI) Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma October 2004 Phase 2
    NCT00722969 Free University Medical Center Non-Small Cell Lung Cancer November 2007 Phase 2
    NCT02971696 Ain Shams University HCC December 2016 Phase 3
    NCT02774187 Sun Yat-sen University Hepatocellular Carcinoma May 2016 Phase 3
    NCT01801163 Indiana University Hepatocellular Carcinoma February 2012 Phase 1
    NCT00955721 University of Miami Cholangiocarcinoma|Biliary Tract Cancer|Gallbladder Cancer August 2009 Phase 1|Phase 2
    NCT00635791 University of Colorado, Denver|Merck Sharp & Dohme Corp.|Bayer Malignant Solid Tumour|Renal Cell Carcinoma|Non Small Cell Lung Carcinoma March 2008 Phase 1
    NCT00466232 HealthPartners Institute Small Cell Carcinoma|Lung Cancer April 2007 Phase 1
    NCT01259193 Fudan University Hepatocellular Carcinoma October 2010 Phase 2
    NCT02748304 Fudan University Hepatocellular Carcinoma April 2016
    NCT00619242 University of Chicago|Bayer Esophageal Cancer June 2006
    NCT03178656 Huazhong University of Science and Technology Portal Vein Tumor Thrombus December 15, 2016 Phase 4
    NCT02292173 H. Lee Moffitt Cancer Center and Research Institute Hepatocellular Cancer|Liver Cancer December 19, 2014 Phase 1
    NCT01306058 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Hepatoma|Liver Neoplasms|Adenoma, Liver Cell|Carcinoma, Hepatocellular|Liver Neoplasms, Experimental February 11, 2011 Phase 1|Phase 2
    NCT00889057 Italian Sarcoma Group Osteosarcoma January 2008 Phase 2
    NCT00126659 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer January 2006 Phase 2
    NCT01271504 Eisai Inc.|PharmaBio Development Inc. Hepatocellular Carcinoma April 2011 Phase 1|Phase 2
    NCT02358395 Sumitomo Dainippon Pharma Co., Ltd. Hepatocellular Carcinoma February 2015 Phase 1
    NCT02143726 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis Refractory Hurthle Cell Thyroid Cancer October 2014 Phase 2
    NCT01187212 Asan Medical Center|Bayer Malignant Neoplasm of Stomach|Effects of Chemotherapy August 2010 Phase 2
    NCT01135056 Singapore General Hospital|National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore|Singapore Clinical Research Institute|Sirtex Medical Hepatocellular Carcinoma July 2010 Phase 3
    NCT02259647 Institute of Liver and Biliary Sciences, India Hepatocellular Carcinoma June 2014
    NCT00678288 Bayer Carcinoma, Renal Cell April 2008 Phase 2
    NCT01141478 Loma Linda University Carcinoma, Hepatocellular August 2010
    NCT00901901 Bayer Carcinoma, Hepatocellular May 21, 2009 Phase 3
    NCT01376453 H. Lee Moffitt Cancer Center and Research Institute|Bayer Rectal Cancer June 2011 Phase 1
    NCT01932177 Hospices Civils de Lyon Metastatic or Locally Advanced Solid Tumors April 2013 Phase 1
    NCT02279719 Boston Biomedical, Inc Hepatocellular Carcinoma December 2014 Phase 1|Phase 2
    NCT00303966 National Cancer Institute (NCI) Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia November 2005 Phase 2
    NCT02227914 Amgen Advanced Hepatocellular Carcinoma December 2014 Phase 1|Phase 2
    NCT01217034 Japan Liver Oncology Group Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasm October 2010 Phase 2
    NCT01724606 Memorial Sloan Kettering Cancer Center|Bayer Breast Cancer|Brain Metastases November 2012 Phase 1
    NCT01047891 JSehouli|Charite University, Berlin, Germany Ovarian Cancer January 2010 Phase 2
    NCT00384969 University of California, San Francisco|Novartis Renal Cell Carcinoma October 2006 Phase 1
    NCT00259129 Bayer Neoplasms August 2005 Phase 1
    NCT00496756 University of Nebraska|National Cancer Institute (NCI)|Bayer Kidney Cancer March 2007 Phase 2
    NCT00265798 National Cancer Institute (NCI) Gastrointestinal Stromal Tumor September 2005 Phase 2
    NCT02747537 Washington University School of Medicine Pediatric Solid Tumors June 24, 2016 Phase 2
    NCT00118170 National Cancer Institute (NCI) Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lym October 2004 Phase 1
    NCT00474929 Mayo Clinic|University of Iowa Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm August 2007 Phase 1|Phase 2
    NCT01272557 PD Dr. med. Matthias Dollinger|Martin-Luther-Universität Halle-Wittenberg Liver Carcinoma December 2010 Phase 2
    NCT01915602 Bayer Carcinoma, Hepatocellular September 27, 2013 Phase 2
    NCT00217620 National Cancer Institute (NCI) Sarcoma March 2006 Phase 2
    NCT00634634 Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals Metastatic Breast Cancer August 2008 Phase 1|Phase 2
    NCT00182689 National Cancer Institute (NCI) Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer July 2005 Phase 2
    NCT01033240 Daiichi Sankyo Inc. Advanced Hepatocellular Carcinoma|Liver Cancer|Hepatic Cancer|Liver Neoplasms March 2010 Phase 2
    NCT00112905 National Cancer Institute (NCI) Adenocarcinoma of the Bladder|Distal Urethral Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Proximal Urethral Cancer|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Urethral Cancer Associated With Invasive B October 2005 Phase 2
    NCT00253578 National Cancer Institute (NCI) Refractory Multiple Myeloma March 2006 Phase 2
    NCT01411423 Bayer Carcinoma, Renal Cell April 2008
    NCT02537158 Chinese Academy of Medical Sciences Hepatocellular Carcinoma August 2015
    NCT01412671 Bayer Carcinoma, Renal Cell February 2008
    NCT00589550 Thomas Olencki|Schering-Plough|Ohio State University Comprehensive Cancer Center Kidney Cancer February 2008 Phase 1
    NCT00405210 Cliniques universitaires Saint-Luc- Université Catholique de Louvain Primary Disease|Prostate Cancer September 2006 Phase 1
    NCT00844168 University of Washington|National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer January 2009 Phase 1
    NCT01683149 H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation|Bayer Solid Tumor January 2013 Phase 1
    NCT00105443 Bayer Carcinoma, Hepatocellular March 2005 Phase 3
    NCT00665990 St. Jude Children's Research Hospital Refractory Solid Tumors|Leukemia November 2007 Phase 1
    NCT02642913 Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.|Mayo Clinic|University of California, San Francisco|University of Southern California|Washington University School of Medicine|Roswell Park Cancer Institute|National Comprehensive Cancer Network|Mayo Clinic Florida Hepatocellular Carcinoma December 2015 Phase 1|Phase 2
    NCT01194869 Emory University|Amgen|Bayer Breast Cancer June 2010 Phase 2
    NCT00390611 SCRI Development Innovations, LLC|Bayer Ovarian Cancer October 2006 Phase 2
    NCT01497444 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Threshold Pharmaceuticals Kidney Cancer|Liver Cancer May 2012 Phase 1|Phase 2
    NCT01844947 Dr Anders Ullén|Bayer|Pierre Fabre Laboratories|Nordic Urothelial Cancer Oncology Group|Karolinska University Hospital Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer June 2012 Phase 1
    NCT00622466 University of Texas Southwestern Medical Center Breast Cancer October 2007 Phase 2
    NCT02354898 Sumitomo Dainippon Pharma Co., Ltd. Advanced Solid Tumors|Hepatocellular Carcinoma March 2015 Phase 1
    NCT00349206 National Cancer Institute (NCI) Melanoma|Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma April 2006 Phase 1
    NCT01411436 Bayer Carcinoma, Hepatocellular May 2009
    NCT01093222 National Cancer Institute (NCI) Extrahepatic Bile Duct Adenocarcinoma|Gallbladder Adenocarcinoma|Gallbladder Adenocarcinoma With Squamous Metaplasia|Hilar Cholangiocarcinoma|Recurrent Extrahepatic Bile Duct Carcinoma|Recurrent Gallbladder Carcinoma|Undifferentiated Gallbladder Carcinoma|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma April 2010 Phase 2
    NCT02450149 Samsung Medical Center Refractory Solid Tumors May 30, 2016
    NCT02187081 Southwest Hospital, China HCC March 15, 2017
    NCT00786110 University of Turin, Italy Adrenocortical Carcinoma April 2008 Phase 2
    NCT01636921 M.D. Anderson Cancer Center|Bayer Lung Cancer January 2008 Phase 2
    NCT00600015 SCRI Development Innovations, LLC|Bayer Non-Small Cell Lung Cancer February 2008 Phase 2
    NCT00971126 National Health Research Institutes, Taiwan|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital Hepatocellular Carcinoma July 2009 Phase 1|Phase 2
    NCT00456716 Swedish Medical Center|Bayer|Amgen Lung Cancer March 2007 Phase 2
    NCT00492752 Bayer Carcinoma, Hepatocellular October 2005 Phase 3
    NCT01840592 Memorial Sloan Kettering Cancer Center|Bayer|National Comprehensive Cancer Network Hepatocellular Carcinoma April 2013 Phase 2
    NCT01585870 Bayer|Onyx Therapeutics, Inc. Neoplasms July 2012 Phase 1
    NCT00908167 St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Bayer/Onyx Acute Myeloid Leukemia|Infantile Leukemia (Both AML and ALL)|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasms|Biphenotypic Leukemia September 2009 Phase 1
    NCT00303797 National Cancer Institute (NCI) Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Multiple Myeloma|Stage IV Chronic Lymphocytic Leukemia|Unspecified Adult Solid Tumor, Protocol Specific December 2005 Phase 1
    NCT00692770 Bayer Carcinoma, Hepatocellular August 2008 Phase 3
    NCT01730937 Radiation Therapy Oncology Group|National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer April 2013 Phase 3
    NCT00326898 National Cancer Institute (NCI)|ECOG-ACRIN Cancer Research Group|NCIC Clinical Trials Group|Southwest Oncology Group|Cancer and Leukemia Group B Stage I Renal Cell Cancer|Stage II Renal Cell Cancer|Stage III Renal Cell Cancer April 2006 Phase 3
    NCT01335074 Philipps University Marburg Medical Center Hepatocellular Carcinoma April 2011 Phase 1|Phase 2
    NCT01861314 National Cancer Institute (NCI) Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia July 3, 2013 Phase 1
    NCT01258608 Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline Carcinoma, Hepatocellular February 2011 Phase 2
    NCT00418496 Ohio State University Comprehensive Cancer Center|Bayer|Novartis Renal Cancer|Melanoma November 8, 2006 Phase 1
    NCT00452218 University of Chicago|Bayer Pulmonary Arterial Hypertension March 2007 Phase 1
    NCT00536575 SCRI Development Innovations, LLC|Bayer Multiple Myeloma November 2007 Phase 1|Phase 2
    NCT01557127 Bayer Carcinoma, Renal Cell November 1, 2011
    NCT00699374 Pfizer Carcinoma, Hepatocellular July 2008 Phase 3
    NCT01223027 Novartis Pharmaceuticals|Novartis Metastatic Renal Cell Carcinoma March 2011 Phase 3
    NCT00494182 M.D. Anderson Cancer Center|Bayer Head and Neck Cancer|Squamous Cell Carcinoma April 2007 Phase 2
    NCT00758381 Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Mario Negri Institute for Pharmacological Research Locally Advanced Pancreatic Cancer August 2007 Phase 2
    NCT00278382 National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma October 2005 Phase 2
    NCT00954135 University of Turin, Italy Breast Cancer September 2007 Phase 2
    NCT00398814 AEterna Zentaris Renal Cancer|Tumors October 2006 Phase 1
    NCT00788099 PharmaMar Advanced Solid Tumors|Lymphomas December 2008 Phase 1
    NCT02575339 Bert O'Neil, MD|Millennium Pharmaceuticals, Inc.|Big Ten Cancer Research Consortium Hepatocellular Carcinoma|Liver Cancer|HCC July 2016 Phase 1|Phase 2
    NCT00747799 Sun Yat-sen University Nasopharyngeal Neoplasms January 2009 Phase 2
    NCT02024087 Acceleron Pharma, Inc. Advanced Adult Hepatocellular Carcinoma June 2014 Phase 1|Phase 2
    NCT00989469 Institut du Cancer de Montpellier - Val d'Aurelle|Bayer Metastatic Colorectal Cancer February 2009 Phase 1|Phase 2
    NCT00101400 Bayer Breast Neoplasms|Breast Cancer February 2004 Phase 2
    NCT01482442 Assistance Publique - Hôpitaux de Paris|Ministry of Health, France Liver Carcinoma December 2011 Phase 3
    NCT01578109 National Cancer Institute (NCI) Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation January 13, 2012
    NCT01075555 Federation Francophone de Cancerologie Digestive|Centre Hospitalier Universitaire Dijon Liver Cancer February 2010 Phase 3
    NCT00542971 M.D. Anderson Cancer Center|Bayer AML|Acute Myeloid Leukemia|Myelodysplastic Disorders October 2007 Phase 1|Phase 2
    NCT00949182 Rutgers, The State University of New Jersey Liver Cancer July 2009 Phase 2
    NCT00752063 The University of Hong Kong Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma September 2007 Phase 2
    NCT00107432 National Cancer Institute (NCI) Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma October 2004 Phase 2
    NCT00245102 National Cancer Institute (NCI) Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Leiomyosarcoma|Adult Malignant Fibrous Histiocytoma|Adult Neurofibrosarcoma|Adult Synovial Sarcoma|Ovarian Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Uterine Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage III Uterine Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Stage IV Uterine Sarcoma|Uterine Carcinosarcoma|Uterine Leiomyosarcoma September 2005 Phase 2
    NCT03097848 Southwest Hospital, China|Chengdu PLA General Hospital|Sichuan Provincial People's Hospital|Sichuan Cancer Hospital and Research Institute|Hunan Cancer Hospital|Cancer Hospital of Guangxi Medical University|The First People's Hospital of Yunnan|Cancer Hospital of Yunnan provinceal|Xiangya Hospital of Central South University|Xinqiao Hospital of Chongqing|The Second Affiliated Hospital of Chongqing Medical University|Henan Cancer Hospital|First Affiliated Hospital of Chongqing Medical University|First Affiliated Hospital of Guangxi Medical University HCC May 4, 2017
    NCT00119249 National Cancer Institute (NCI) Stage III Melanoma|Stage IV Melanoma June 2005 Phase 2
    NCT00828594 Novartis Pharmaceuticals|Novartis Hepatocellular Carcinoma December 2008 Phase 1
    NCT01264705 University of Texas Southwestern Medical Center Hepatocellular Carcinoma|Liver Cancer January 2011 Phase 1|Phase 2
    NCT00722072 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Breast Cancer July 2008 Phase 2
    NCT00712855 Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline Hepatocellular Carcinoma June 2008 Phase 1
    NCT03211416 Roswell Park Cancer Institute|National Cancer Institute (NCI) Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma August 15, 2017 Phase 1|Phase 2
    NCT00855218 Bayer Carcinoma, Hepatocellular March 2009 Phase 2
    NCT00826540 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer September 2009 Phase 2
    NCT00098540 National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer December 2004 Phase 2
    NCT00131989 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia June 2005 Phase 1
    NCT00619996 Italian Trial in Medical Oncology Prostate Cancer March 2007 Phase 2
    NCT00627835 British Columbia Cancer Agency Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) Phase 1
    NCT00126503 National Cancer Institute (NCI) Chromophobe Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Renal Cell Cancer May 2005 Phase 1|Phase 2
    NCT00096512 National Cancer Institute (NCI) Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Na October 2004 Phase 2
    NCT00244972 National Cancer Institute (NCI) Advanced Malignant Neoplasm October 2005 Phase 1
    NCT00044512 Bayer Carcinoma, Hepatocellular August 2002 Phase 2
    NCT03009461 Peking University HepatoCellular Carcinoma|Portal Vein Thrombosis June 1, 2017 Phase 2
    NCT00869570 Swiss Group for Clinical Cancer Research Colorectal Cancer March 2009 Phase 1|Phase 2
    NCT00734526 M.D. Anderson Cancer Center|Bayer Glioblastoma|Gliosarcoma December 2008 Phase 1
    NCT01903694 Centre Hospitalier Universitaire Dijon Child-Pugh A Hepatocellular Carcinoma March 2010 Phase 3
    NCT00473486 University Hospital Muenster|Bayer|Eli Lilly and Company Carcinoma, Non-Small-Cell Lung May 2007 Phase 1|Phase 2
    NCT02988440 Novartis Pharmaceuticals|Novartis Hepatocellular Carcinoma April 20, 2017 Phase 1
    NCT00217646 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With October 2005 Phase 1
    NCT01715441 Institut du Cancer de Montpellier - Val d'Aurelle Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors September 2012 Phase 2
    NCT00478374 University of Bern Hepatocellular Carcinoma May 2007 Phase 1
    NCT00424385 Oncology Specialists, S.C. Prostate Cancer January 2007 Phase 1
    NCT01817751 Virginia Commonwealth University|National Cancer Institute (NCI) Glioblastoma|Glioma|Recurrent Adult Brain Neoplasm April 11, 2013 Phase 2
    NCT00509613 Radboud University|Bayer Advanced Solid Tumor|Refractory to Standard Therapies June 2007 Phase 1
    NCT01265576 Vicus Therapeutics HCC December 2010 Phase 2
    NCT01008566 National Cancer Institute (NCI) Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma August 2009 Phase 1
    NCT00101413 Bayer|Amgen Cancer|Carcinoma, Non-Small Cell Lung April 2004 Phase 2
    NCT00492297 Bayer Melanoma April 2005 Phase 2
    NCT00119639 Bayer Kidney Diseases June 2005 Phase 1
    NCT01377025 Prof. Dr. med. Max. E. Scheulen|ClinAssess GmbH|University Hospital, Essen Uveal Melanoma June 2011 Phase 2
    NCT00095966 National Cancer Institute (NCI) Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer September 2004 Phase 2
    NCT00126620 University Health Network, Toronto|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2005 Phase 1
    NCT00823290 University of Erlangen-Nürnberg|University of Erlangen-Nürnberg Medical School Hepatocellular Carcinoma January 2009 Phase 1
    NCT00779311 Accelerated Community Oncology Research Network|Bayer Metastatic Colorectal Cancer October 2008 Phase 1
    NCT01348503 Indiana University School of Medicine|Celgene Corporation|Indiana University Hepatocellular Carcinoma May 2011 Phase 1
    NCT00828074 City of Hope Medical Center|National Cancer Institute (NCI) Breast Cancer November 2008 Phase 1|Phase 2
    NCT00255658 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2005 Phase 1
    NCT01171482 Seoul National University Hospital Carcinoma, Hepatocellular November 2015 Phase 2
    NCT01159301 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16) June 2010 Phase 1
    NCT01204177 Bayer Carcinoma, Hepatocellular December 2010 Phase 2
    NCT01775501 Massachusetts General Hospital Hepatocellular Cancer January 2013 Phase 2
    NCT01839630 Bayer Carcinoma, Hepatocellular May 30, 2013
    NCT01616186 Andrea Harzstark|Novartis|University of California, San Francisco Locally Metastatic Malignant Neoplasm July 2012 Phase 2
    NCT00621686 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Brain and Central Nervous System Tumors September 2008 Phase 2
    NCT01405573 National Cancer Institute, Naples Advanced Adult Hepatocellular Carcinoma July 2011 Phase 3
    NCT02143401 National Cancer Institute (NCI) Child-Pugh Class A|Child-Pugh Class B|Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm November 7, 2014 Phase 1
    NCT00238121 National Cancer Institute (NCI) Recurrent Uterine Sarcoma|Stage III Uterine Sarcoma|Stage IV Uterine Sarcoma|Uterine Carcinosarcoma February 2005 Phase 2
    NCT02989870 H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer March 27, 2017 Phase 1
    NCT00984282 Bayer|Amgen Thyroid Neoplasms October 2009 Phase 3
    NCT00131911 National Cancer Institute (NCI) Gastrinoma|Glucagonoma|Insulinoma|Metastatic Gastrointestinal Carcinoid Tumor|Neuroendocrine Tumor|Pancreatic Polypeptide Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma|WDHA Syndrome June 2005 Phase 2
    NCT01015833 National Cancer Institute (NCI) Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage D Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma February 2010 Phase 3
    NCT01450384 Virginia Commonwealth University|National Cancer Institute (NCI) Unspecified Adult Solid Tumor October 2011 Phase 1
    NCT00609401 Italian Trial in Medical Oncology Metastatic Disease|Renal Cell Carcinoma November 2006 Phase 2
    NCT00448149 The Methodist Hospital System|Novartis Pharmaceuticals Carcinoma, Renal Cell December 2006 Phase 1|Phase 2
    NCT01751763 Bayer Carcinoma, Hepatocellular July 9, 2013
    NCT00889343 AIO-Studien-gGmbH Colorectal Neoplasms March 2009 Phase 2
    NCT00389285 ZymoGenetics Carcinoma, Renal Cell October 2006 Phase 1|Phase 2
    NCT01276210 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Tumors Metastatic to Brain February 2011 Phase 1
    NCT01624285 Jonsson Comprehensive Cancer Center|Bayer Adult Primary Hepatocellular Carcinoma|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer July 2012 Phase 2
    NCT00301847 National Cancer Institute (NCI) Kidney Cancer|Metastatic Cancer November 2005 Phase 2
    NCT01320111 Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|iOMEDICO AG Metastatic Breast Cancer July 1, 2010 Phase 2
    NCT00632541 Hoosier Cancer Research Network|Genentech, Inc.|Bayer|Amgen Metastatic Breast Cancer October 2007 Phase 2
    NCT02627963 AVEO Pharmaceuticals, Inc. Carcinoma, Renal Cell April 2016 Phase 3
    NCT00498836 Clavis Pharma Malignant Melanoma March 2007 Phase 2
    NCT01666756 City of Hope Medical Center|National Cancer Institute (NCI) Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Advanced Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma May 6, 2013 Phase 1
    NCT00281957 National Cancer Institute (NCI) Recurrent Melanoma|Stage IV Melanoma August 2007 Phase 2
    NCT00789763 Grupo Espanol Multidisciplinario del Cancer Digestivo Pancreatic Cancer December 2007 Phase 1
    NCT00134069 National Cancer Institute (NCI) Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer June 2005 Phase 1
    NCT01933945 Bayer Carcinoma, Hepatocellular June 26, 2013
    NCT01170104 Chung-Ang University|Gyeongsang National University Hospital Hepatocellular Carcinoma June 2009 Phase 2
    NCT02035527 Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Na April 14, 2014 Phase 1|Phase 2
    NCT00919061 Memorial Sloan Kettering Cancer Center|Bayer Extrahepatic Bile Duct Cancer|Gallbladder Cancer August 2009 Phase 2
    NCT01434602 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Brain Tumor|Glioblastoma|Anaplastic Glioma October 21, 2015 Phase 1|Phase 2
    NCT00126594 National Cancer Institute (NCI)|M.D. Anderson Cancer Center Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer June 2005 Phase 2
    NCT00464919 National Taiwan University Hospital Hepatocellular Carcinoma April 2007 Phase 2
    NCT01131689 Samsung Medical Center Hepatocellular Carcinoma September 2009 Phase 1
    NCT02129322 Zhejiang University Hepatocellular Carcinoma July 2015 Phase 2
    NCT01897038 Hoffmann-La Roche Carcinoma, Hepatocellular September 2013 Phase 1
    NCT00865709 Bayer|Amgen Metastatic Colorectal Cancer March 2009 Phase 2
    NCT02066181 National Cancer Institute (NCI) Desmoid-Type Fibromatosis March 21, 2014 Phase 3
    NCT01445080 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Leukemia|With AML and FLT3-ITD Mutations August 23, 2006 Phase 1
    NCT01761266 Eisai Limited|Eisai Inc. Hepatocellular Carcinoma (HCC) March 14, 2013 Phase 3
    NCT00217399 National Cancer Institute (NCI) Recurrent Breast Cancer|Stage IV Breast Cancer June 2005 Phase 1|Phase 2
    NCT01687673 University of California, San Francisco|Robert H. Lurie Cancer Center|Pfizer Hepatocellular Carcinoma October 5, 2012 Phase 2
    NCT01234337 Bayer|Onyx Therapeutics, Inc. Breast Cancer February 21, 2011 Phase 3
    NCT00096395 National Cancer Institute (NCI) Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer September 2004 Phase 2
    NCT00544817 SCRI Development Innovations, LLC|Bayer Glioblastoma Multiforme April 2007 Phase 2
    NCT00114244 National Cancer Institute (NCI) Stage IV Pancreatic Cancer December 2004 Phase 2
    NCT00586495 Bayer Carcinoma, Renal Cell December 2005 Phase 2
    NCT00941863 Bayer|Amgen Carcinoma July 2002 Phase 1
    NCT01518413 HMeany|Children's Research Institute Rhabdomyosarcoma and Other Soft Tissue Sarcomas|Ewing's Sarcoma Family of Tumors|Osteosarcoma|Neuroblastoma|Brain Tumors December 2011 Phase 1
    NCT00558636 Bayer Carcinoma, Non-Small-Cell Lung September 2007 Phase 3
    NCT01908322 Bayer Carcinoma, Hepatocellular August 2013
    NCT00098618 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer October 2004 Phase 2
    NCT00329641 National Cancer Institute (NCI) Ciliary Body and Choroid Melanoma, Medium/Large Size|Extraocular Extension Melanoma|Iris Melanoma|Metastatic Intraocular Melanoma|Recurrent Intraocular Melanoma February 2011 Phase 2
    NCT00111020 Bayer Carcinoma, Renal Cell June 2005 Phase 3
    NCT00436579 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific January 2007 Phase 1
    NCT00573690 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific September 2007 Phase 1
    NCT01158287 Cancer Trials Ireland Esophageal Cancer|Gastric Cancer February 2009 Phase 2
    NCT00101114 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer September 2004 Phase 2
    NCT01262482 Grupo Espanol Multidisciplinario del Cancer Digestivo Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) October 2008 Phase 2
    NCT00837876 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Pancreatic Cancer October 2008 Phase 2
    NCT02576509 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd Hepatocellular Carcinoma November 25, 2015 Phase 3
    NCT01383343 National Cancer Institute (NCI) Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer August 2011 Phase 1
    NCT00812175 Bayer Carcinoma, Hepatocellular January 2009
    NCT00121264 National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific March 2005 Phase 1
    NCT00117637 Bayer Carcinoma, Renal Cell June 2005 Phase 2
    NCT02400788 Yakult Honsha Co., LTD Hepatocellular Carcinoma April 2013 Phase 1|Phase 2
    NCT00121251 National Cancer Institute (NCI) Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer April 19, 2005 Phase 1|Phase 2
    NCT01245582 Sanofi Hepatic Neoplasm Malignant July 2011 Phase 3
    NCT02599090 M.D. Anderson Cancer Center|Bayer Glioblastoma|Gliosarcoma December 2008 Phase 2
    NCT00791778 Bayer Ovarian Neoplasms November 2008 Phase 2
    NCT00522301 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bayer Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer July 2007 Phase 2
    NCT03164382 Sun Yat-sen University Liver Cancer|Hepatic Carcinoma January 1, 2017 Phase 3
    NCT01215266 Association of Urogenital Oncology (AUO)|University Hospital, Essen Bladder Cancer October 2006 Phase 2
    NCT00663741 Bayer Gastric Cancer May 2008 Phase 1
    NCT00093457 NCIC Clinical Trials Group|National Cancer Institute (NCI)|Canadian Cancer Trials Group Prostate Cancer July 2004 Phase 2
    NCT02270788 St. Jude Children's Research Hospital|Arog Pharmaceuticals, Inc.|Ohio State University Acute Myeloid Leukemia April 2, 2015 Phase 1
    NCT00238212 National Cancer Institute (NCI) Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Squamous Cell Carcinoma of the Gallbladder|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer October 2005 Phase 2
    NCT01502410 National Cancer Institute (NCI) Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors January 2012 Phase 2
    NCT00794859 King's College London|Bayer Mesothelioma October 2008 Phase 2
    NCT01009593 Abbott Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Carcinoma, Hepatocellular|Liver Diseases|Neoplasms by Histologic Type|Digestive System Neoplasms|Carcinoma|Liver Neoplasms|Neoplasms|Neoplasms by Site|Digestive System Diseases|Adenocarcinoma|Neoplasms, Glandular and Epithelial January 2010 Phase 3
    NCT00726986 Afshin Dowlati, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center Lung Cancer July 2008 Phase 2
    NCT02460991 Boston Scientific Corporation Hepatocellular Carcinoma|Hepatoma|Liver Cell Carcinoma November 2015
    NCT00976170 Chugai Pharmaceutical|Hoffmann-La Roche Hepatocellular Carcinoma September 2009 Phase 1
    NCT01078961 Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc. Melanoma September 2010 Phase 1
    NCT00657254 Bayer Neoplasm|Metastasis December 2002 Phase 2
    NCT01703455 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Salivary Gland Cancer September 2010 Phase 2
    NCT01728948 Bayer Carcinoma, Renal Cell December 2012 Phase 4
    NCT03140332 Centre Hospitalier Universitaire, Amiens Hepatocellular Carcinoma|Perfusion Scanner October 21, 2016
    NCT00727532 Northwestern University|National Cancer Institute (NCI) Hereditary Clear Cell Renal Cell Carcinoma|Kidney Cancer July 2008
    NCT00981162 Roswell Park Cancer Institute|National Cancer Institute (NCI) Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific August 2009 Phase 1
    NCT00526799 Daniela Matei, MD|Bayer|Hoosier Cancer Research Network Ovarian Cancer September 2007 Phase 1|Phase 2
    NCT02908165 Yale University Hepatocellular Carcinoma June 2016 Phase 2
    NCT01232296 Novartis Pharmaceuticals|Novartis Hepatocellular Carcinoma July 2011 Phase 2
    NCT00449280 University of Chicago|Bayer Advanced Solid Tumor November 2006 Phase 1
    NCT00872014 Amgen Advanced Hepatocellular Carcinoma|Inoperable Hepatocellular Carcinoma August 2009 Phase 2
    NCT00873002 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Liver Cancer March 2009 Phase 1
    NCT00494299 Bayer Carcinoma, Hepatocellular April 2006 Phase 3
    NCT01253070 National Cancer Institute (NCI) Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1|Acute Myeloid Leukemia With a Variant RARA Translocation|Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214|Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Acute Myeloid Leukemia With Variant MLL Translocations|Untreated Adult Acute Myeloid Leukemia April 2011 Phase 2
    NCT02050919 OHSU Knight Cancer Institute|Bayer|National Cancer Institute (NCI) Stage IIB Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma December 2013 Phase 2
    NCT01004003 Boehringer Ingelheim Carcinoma, Hepatocellular October 2009 Phase 2
    NCT00661830 PD Dr Markus Möhler|Johannes Gutenberg University Mainz|Interdisciplinary Center for Clinical Trials (IZKS) Adenocarcinoma May 2008 Phase 2
    NCT00874874 Centre Oscar Lambret|National Cancer Institute (NCI) Sarcoma May 2008 Phase 2
    NCT02240433 Eli Lilly and Company Hepatocellular Carcinoma November 2014 Phase 1
    NCT00867321 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Liver Cancer April 2009 Phase 1|Phase 2
    NCT01182272 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI) Liver Cancer May 2010 Phase 2
    NCT01187199 M.D. Anderson Cancer Center Advanced Cancer August 2010 Phase 1
    NCT00634751 University of Wisconsin, Madison|Bayer|Sanofi Pancreatic Neoplasms|Bile Duct Neoplasms February 2008 Phase 1|Phase 2
    NCT00079612 Bayer|Amgen Carcinoma, Renal Cell September 2002 Phase 2
    NCT00096434 National Cancer Institute (NCI) Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer September 2004 Phase 2
    NCT00449033 Bayer Carcinoma, Non-Small-Cell Lung February 2007 Phase 3
    NCT01353794 Bayer Carcinoma, Renal Cell December 2014 Phase 4
    NCT00335764 National Cancer Institute (NCI) Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor April 2006 Phase 1|Phase 2
    NCT00352859 Bayer Carcinoma, Renal Cell August 2006 Phase 4
    NCT00822848 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Sarcoma February 2009 Phase 1
    NCT00454194 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lung Cancer September 2007 Phase 2
    NCT00696696 New York University School of Medicine|Bayer|OSI Pharmaceuticals Pancreatic Cancer September 2007 Phase 2
    NCT00095693 National Cancer Institute (NCI) Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer October 2004 Phase 2
    NCT00452387 Accelerated Community Oncology Research Network|Bayer Metastatic Prostate Cancer May 2007 Phase 2
    NCT00687674 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm August 2008 Phase 1|Phase 2
    NCT00607438 Veeda Oncology|Bayer|Celgene Corporation Breast Cancer September 2007 Phase 2
    NCT00329719 National Cancer Institute (NCI) Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor March 2006 Phase 1|Phase 2
    NCT00606866 University of Chicago|Bayer Metastatic Renal Cell Carcinoma July 2004 Phase 3
    NCT00875615 University of Miami Liver Cancer December 2008 Phase 2
    NCT00544167 SCRI Development Innovations, LLC|Bayer Breast Cancer May 2007
    NCT00387751 National Cancer Institute (NCI) Recurrent Melanoma|Stage III Skin Melanoma|Stage IV Skin Melanoma August 2006 Phase 2
    NCT00445588 National Cancer Institute (NCI) Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor January 2007 Phase 2
    NCT00490685 Istituto Clinico Humanitas Carcinoma, Hepatocellular April 2007 Phase 2
    NCT00496301 Spanish Oncology Genito-Urinary Group Carcinoma, Renal Cell November 2006 Phase 2
    NCT00474786 Pfizer Renal Cell Carcinoma September 2007 Phase 3
    NCT00939627 National Cancer Institute (NCI) Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Na July 2009 Phase 2
    NCT00110019 National Cancer Institute (NCI) Mucosal Melanoma|Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma June 2005 Phase 3
    NCT01988493 Merck KGaA Carcinoma, Hepatocellular January 6, 2014 Phase 1|Phase 2
    NCT00492258 Medical Research Council|National Cancer Institute (NCI) Kidney Cancer June 2007 Phase 3
    NCT00378703 National Cancer Institute (NCI) Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer September 14, 2007 Phase 2
    NCT00417248 Nasser Hanna, M.D.|Bayer|Amgen|Walther Cancer Institute|Hoosier Cancer Research Network Non-Small Cell Lung Cancer June 2007 Phase 1|Phase 2
    NCT00330421 National Cancer Institute (NCI) Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Osteosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Osteosarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma June 2006 Phase 2
    NCT00602576 University of Pennsylvania|National Cancer Institute (NCI) Melanoma (Skin) January 2005 Phase 2
    NCT00941967 Institut du Cancer de Montpellier - Val d'Aurelle|National Cancer Institute (NCI) Liver Cancer December 2008 Phase 2
    NCT00589420 University of Pennsylvania|National Cancer Institute (NCI) Prostate Cancer October 2006 Phase 2
    NCT00096200 National Cancer Institute (NCI) Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma August 2004 Phase 2
    NCT01004978 National Cancer Institute (NCI) Hepatocellular Carcinoma|Non-Resectable Hepatocellular Carcinoma October 28, 2009 Phase 3
    NCT00492986 Bayer Carcinoma, Renal Cell October 2005 Phase 3
    NCT00623402 University of Schleswig-Holstein|Dermatologic Cooperative Oncology Group Melanoma January 2008 Phase 2
    NCT00466752 University of Washington|National Cancer Institute (NCI) Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer December 2006 Phase 2
    NCT00661375 Bayer Carcinoma, Renal Cell November 2004 Phase 2
    NCT00792350 Bayer Carcinoma, Hepatocellular April 2008
    NCT00541021 Institut Paoli-Calmettes|National Cancer Institute (NCI) Pancreatic Cancer December 2006 Phase 3
    NCT00565968 Duke University|National Cancer Institute (NCI) Melanoma (Skin) October 2007 Phase 1
    NCT01409499 Sun Yat-sen University Hepatectomy|Hepatocellular Carcinoma|Sorafenib January 2011 Phase 4
    NCT00732914 Sponsor GmbH|iOMEDICO AG Renal Cell Carcinoma January 2009 Phase 3
    NCT00881751 Medical University of South Carolina Liver Cancer March 2009 Phase 2
    NCT00073307 Bayer|Amgen Carcinoma, Renal Cell November 2003 Phase 3
    NCT01887717 BTG International Inc.|Biocompatibles UK Ltd Hepatocellular Carcinoma June 2013 Phase 3
    NCT00499525 Northwestern University|Amgen Breast Cancer June 2007 Phase 2
    NCT02517736 University Hospital, Caen Uveal Melanoma February 2012 Phase 2
    NCT01308723 Hoffmann-La Roche Carcinoma, Hepatocellular March 2011 Phase 1
    NCT00858871 Bristol-Myers Squibb Hepato Cellular Carcinoma (HCC) May 2009 Phase 3
    NCT02616692 Bayer Hepatocellular Cancer May 2016
    NCT01183663 M.D. Anderson Cancer Center|Celgene Advanced Cancers August 2010 Phase 1
    NCT02645981 Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Tigermed Consulting Co., Ltd HCC March 2016 Phase 2|Phase 3
    NCT00895674 Bayer Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced) July 2006
    NCT02728050 University of Washington|National Cancer Institute (NCI) Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myeloproliferative Neoplasm December 2016 Phase 1|Phase 2
    NCT00547443 Simmons Cancer Center|National Cancer Institute (NCI) Lung Cancer July 2007 Phase 1|Phase 2
    NCT00906373 Eli Lilly and Company Hepatocellular Carcinoma May 2009 Phase 2
    NCT00661180 Bayer Chronic Myelogenous Leukemia January 2004 Phase 2
    NCT01042041 Abramson Cancer Center of the University of Pennsylvania Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer September 2009 Phase 1
    NCT00538005 San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI) Melanoma (Skin) May 2007 Phase 1|Phase 2
    NCT00110994 Bayer|Amgen Cancer|Melanoma April 2005 Phase 2
    NCT00467025 Amgen Advanced Renal Cell Carcinoma May 2007 Phase 2
    NCT00771147 Bayer Carcinoma, Renal Cell|Carcinoma, Renal Cell (Advanced) June 2008
    NCT02349867 Virginia Commonwealth University|National Cancer Institute (NCI) Pancreatic Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer January 29, 2015 Phase 1
    NCT01754987 Thomas Jefferson University Metastatic Hepatocellular Carcinoma|Advanced Liver Cancer September 2012 Phase 1|Phase 2
    NCT00573755 Mayo Clinic|National Cancer Institute (NCI) Breast Cancer December 2007 Phase 2
    NCT00492505 San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI) Melanoma (Skin) April 2007 Phase 2
    NCT00493636 Accelerated Community Oncology Research Network|Amgen Breast Cancer June 2007 Phase 2
    NCT00861419 Amgen Advanced Solid Tumors December 2005 Phase 1
    NCT01664182 National Cancer Institute (NCI) Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer August 1, 2012 Phase 2
    NCT01069328 Bayer Carcinoma, Non-Small-Cell Lung|Lung Cancer July 2006 Phase 1
    NCT01012011 Bayer Carcinoma, Hepatocellular|Carcinoma, Renal Cell September 2009
    NCT00111007 Bayer|Amgen Melanoma May 2005 Phase 3
    NCT01371981 National Cancer Institute (NCI) Leukemia Cutis|Myeloid Sarcoma|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Myeloid Neoplasm June 20, 2011 Phase 3
    NCT01011010 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Liver Cancer July 2009 Phase 1
    NCT00406601 Istituto Clinico Humanitas Sarcoma, Soft Tissue November 2006 Phase 2
    NCT00801385 Yonsei University|National Cancer Institute (NCI) Lung Cancer September 2008 Phase 2
    NCT00108953 Bayer Carcinoma, Hepatocellular April 2005 Phase 2
    NCT00811759 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) Melanoma (Skin) June 2007 Phase 1|Phase 2
    NCT01357486 University Hospital, Bordeaux|Federation Francophone de Cancerologie Digestive|UNICANCER Hepatocellular Carcinoma|CHILD B November 14, 2011 Phase 2
    NCT02436902 Guangxi Medical University Hepatocellular Carcinoma February 2016 Phase 3
    NCT00673361 Duke University|Bayer Melanoma March 2007 Phase 2
    NCT01222676 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI) Bladder Cancer October 2010 Phase 2
    NCT01498952 MedImmune LLC Unresectable or Metastatic Hepatocellular Carcinoma (HCC) January 2012 Phase 1
    NCT01324076 University College, London|National Cancer Institute (NCI) Liver Cancer November 2010 Phase 3
    NCT02209441 Chinese Academy of Medical Sciences Gastric Cancer.
    NCT02178358 Eli Lilly and Company Hepatocellular Carcinoma August 2014 Phase 2
    NCT00678392 Pfizer Kidney Neoplasms September 2008 Phase 3
    NCT00987935 Boehringer Ingelheim Carcinoma, Hepatocellular October 2009 Phase 2
    NCT00543504 M.D. Anderson Cancer Center Advanced Cancer October 2007 Phase 1
    NCT01381601 GlaxoSmithKline Carcinoma, Renal Cell March 2011
    NCT02406521 Dana-Farber Cancer Institute|Bayer Metastatic Renal Cell Carcinoma April 2015 Phase 1
    NCT01658878 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd Hepatocellular Carcinoma September 26, 2012 Phase 1|Phase 2
    NCT00920816 Pfizer Kidney Neoplasms August 25, 2009 Phase 3
    NCT00110344 Bayer Carcinoma, Renal Cell November 2005 Phase 2
    NCT01576185 Children's Oncology Group|National Cancer Institute (NCI) Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies May 2012
    NCT01381614 GlaxoSmithKline Carcinoma, Renal Cell March 2011
    NCT02794337 Tata Memorial Hospital Carcinoma, Hepatocellular December 2014 Phase 2|Phase 3
    NCT00829231 Bayer Liver Disease January 2009 Phase 1
    NCT03132454 M.D. Anderson Cancer Center|Pfizer Hematopoietic/Lymphoid Cancer|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia September 2017 Phase 1
    NCT02303444 Bayer Thyroid Neoplasms April 8, 2015
    NCT00791544 Sanofi Liver Carcinoma November 2008 Phase 1|Phase 2
    NCT02973204 University of Aarhus|Aarhus University Hospital Carcinoma, Hepatocellular|Neuroendocrine Tumors November 2016
    NCT01246986 Eli Lilly and Company Carcinoma, Hepatocellular March 2011 Phase 2
    NCT02015728 Seattle Children's Hospital|Cures Within Reach Recurrent Childhood Brain Tumor December 2013
    NCT01195649 Bayer Carcinoma, Renal Cell December 2010
    NCT01197170 M.D. Anderson Cancer Center Solid Tumors|Advanced Cancer September 2010 Phase 1
    NCT01449825 GlaxoSmithKline Carcinoma, Renal Cell December 2010
    NCT01190241 VU University Medical Center|VitrOmics BV Advanced Solid Tumors|Inoperable|Metastasis August 2010
    NCT01248247 M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|GlaxoSmithKline|Novartis Lung Cancer June 2011 Phase 2
    NCT00495872 M.D. Anderson Cancer Center Solid Tumors June 2007 Phase 1
    NCT01620216 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia May 2012 Phase 2
    NCT01441388 Pfizer Carcinoma, Renal Cell|Glioblastoma|Carcinoma, Hepatocellular December 2011 Phase 1
    NCT02013089 Sun Yat-sen University Gastrointestinal Cancers December 2013
    NCT02559778 Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals Neuroblastoma September 2015 Phase 1
    NCT02029001 Centre Leon Berard|National Cancer Institute, France Malignant Solid Neoplasms February 2014 Phase 2
    NCT02560012 The University of Texas Health Science Center, Houston Carcinoma, Renal Cell December 2015 Phase 2
    NCT02412475 Michael Burke|Children's Hospitals and Clinics of Minnesota|Medical College of Wisconsin Leukemia, Acute Myeloid February 2015 Phase 1
    NCT02423239 e-Therapeutics PLC Hepatocellular Carcinoma|Pancreatic Cancer April 2015 Phase 1
    NCT02779283 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Untreated Adult Acute Myeloid Leukemia December 2015 Phase 1
    NCT01946529 St. Jude Children's Research Hospital|University of Tennessee Health Science Center|University of Florida|Nemours Children's Clinic Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor November 2013 Phase 2
    NCT02638428 Samsung Medical Center|Ministry of health & welfare, Republic of Korea Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML December 2015 Phase 2
    NCT01871766 St. Jude Children's Research Hospital Rhabdomyosarcoma December 4, 2013 Phase 2
    NCT01771458 Institut Curie Reccurent/Metastatic Solid Tumor Disease October 2012 Phase 2
    NCT03164057 St. Jude Children's Research Hospital Acute Myeloid Leukemia|Myelodysplastic Syndromes June 15, 2017 Phase 2
    NCT03017326 University of Birmingham|Fundació Institut Germans Trias i Pujol|University of Padua|University of Newcastle Upon-Tyne|University Hospital Munich|University Hospital, Bonn|University of Kiel|University Hospital Tuebingen|Medical University of Gdansk Hepatoblastoma|Carcinoma, Hepatocellular May 2017 Phase 3
    NCT01636908 VU University Medical Center Cancer|Advanced Solid Tumors August 2011
    NCT02836847 Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer July 2016 Phase 2
    NCT00811993 Hoffmann-La Roche Neoplasms February 2009 Phase 1
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 2.1513 mL 10.7566 mL 21.5132 mL
    5 mM 0.4303 mL 2.1513 mL 4.3026 mL
    10 mM 0.2151 mL 1.0757 mL 2.1513 mL
    Kinase Assay
    [1]

    To test compound inhibition against various RAF kinase isoforms, Sorafenib is added to a mixture of Raf-1 (80 ng), wt BRAF, or V599E BRAF (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The RAF kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ-[33P]ATP (400 Ci/mol) and incubated at 32°C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Sorafenib is dissolved in DMSO and stored, and then diluted with appropriate media before use[1].

    The MDA-MB-231 human mammary adenocarcinoma cell lines are plated at 2×105 cells per well in 12-well tissue culture plates in DMEM growth media (10% heat-inactivated FCS) overnight. Cells are washed once with serum-free media and incubated in DMEM supplemented with 0.1% fatty acid-free BSA containing various concentrations of BAY 43-9006 (0.01, 0.03 , 0.1, 0.3, 1, 3 μM) in 0.1% DMSO for 120 minutes to measure changes in basal pMEK 1/2, pERK 1/2, or pPKB. Cells are washed with cold PBS (PBS containing 0.1 mM vanadate) and lysed in a 1% (v/v) Triton X-100 solution containing protease inhibitors. Lysates are clarified by centrifugation, subjected to SDS-PAGE, transferred to nitrocellulose membranes, blocked in TBS-BSA, and probed with anti-pMEK 1/2 (Ser217/Ser221; 1:1000), anti-MEK 1/2, anti-pERK 1/2 (Thr202/Tyr204; 1:1000), anti-ERK 1/2, anti-pPKB (Ser473; 1:1000), or anti-PKB primary antibodies. Blots are developed with horseradish peroxidase (HRP)-conjugated secondary antibodies and developed with Amersham ECL reagent on Amersham Hyperfilm[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][2]

    Sorafenib is dissolved in Cremophor EL/ethanol (50:50; Cremophor EL, 95% ethyl alcohol) at 4-fold (4×) of the highest dose, foil wrapped, and stored at room temperature (Mice)[1].

    Mice[1]
    Female NCr-nu/nu mice are used. Mice bearing 75 to 150 mg tumors are treated orally with Sorafenib (7.5 to 60 mg/kg), administered daily for 9 days. In each model, Sorafenib produces dose-dependent tumor growth inhibition with no evidence of toxicity, as measured by increased weight loss relative to control animals or drug-related lethality. In parallel to the antitumor efficacy studies, additional groups of four mice bearing 100 to 200 mg tumors are treated orally with vehicle or Sorafenib (30 to 60 mg/kg), administered daily for 5 days, which is the shortest treatment duration producing complete tumor stasis in the treated groups.
    Rat[2]
    In the study, 100- to 120-g male albino rats are utilized. After acclimatization period, rats are weighed and randomly divided into three groups: Group 1 (normal control group; n=10) is given the vehicle daily for 8 weeks. Group 2 (DENA group; n=15) receive i.p. single dose of 200 mg/kg DENA. Group 3 (Sorafenib group; n=12) is given Sorafenib orally at a dose of 10 mg/kg daily for 2 weeks, 6 weeks after DENA i.p. injection. At the end of the experiment (8 weeks), rats are weighed, anesthetized by ether, and killed, and their livers are dissected. Fresh liver is washed twice with ice-cold saline, dried on clean paper towel, and weighed. Liver index is calculated as liver weight (g)/final body weight (g)×100. The liver is divided into five portions: one portion is preserved in 10 % formalin for histopathological examination and the other portions are immediately frozen in liquid nitrogen and stored at −80°C. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    464.83

    Formula

    C₂₁H₁₆ClF₃N₄O₃

    CAS No.

    284461-73-0

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 45 mg/mL

    Sorafenib is dissolved in DMSO and then diluted with saline (the final DMSO concentration is <0.1%)[3].
    Sorafenib is prepared in vehicle (saline)[4].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    References

    Purity: 99.83%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Sorafenib
    Cat. No.:
    HY-10201
    Quantity: